Free Stock & ETF Comparisons
1622+ side-by-side comparisons with AI scores, valuation metrics, performance charts, analyst targets, and investor takeaways. No sign-in required.
- AI investment scores (0–100) for each stock
- Valuation metrics: P/E, forward P/E, PEG, EV/EBITDA
- Performance charts across 1M to 10Y timeframes
- Analyst price targets and upside estimates
- AI-written investor thesis and side-by-side takeaways
Browse Comparisons
Compare Broadcom and Qualcomm by custom AI ASIC revenue, smartphone SoC dominance, software revenue mix, dividend yield, and analyst upside.
Compare Texas Instruments and Analog Devices by industrial and automotive end markets, free cash flow generation, dividend growth, capital return policy, and valuation.
Compare TI and Microchip Technology by microcontroller market share, industrial recovery exposure, dividend track record, debt levels, and long-term valuation.
Compare KLA Corporation and Lam Research by process control vs etch/deposition exposure, NAND recovery leverage, gross margins, and analyst upside.
Compare Lam Research and Applied Materials by deposition vs etch specialization, advanced packaging exposure, China revenue risk, margins, and valuation.
Compare Applied Materials and KLA by addressable market breadth, AI chip capex leverage, customer concentration, margins, and long-term return potential.
Compare ON Semiconductor and Wolfspeed by silicon carbide revenue ramp, EV platform design wins, manufacturing capacity, profitability, and valuation.
Compare Monolithic Power Systems and Analog Devices by AI server power delivery exposure, product breadth, gross margins, revenue growth, and forward valuation.
Compare STMicroelectronics and ON Semiconductor by SiC market share, automotive exposure, geographic revenue mix, margins, and upside potential.
Compare MongoDB and Snowflake by developer adoption, consumption revenue model, AI workload traction, net revenue retention, gross margin, and forward valuation.
Compare Datadog and Dynatrace by platform breadth, AI observability features, net revenue retention, enterprise vs SMB mix, and valuation.
Compare HubSpot and Salesforce by SMB vs enterprise focus, AI product adoption, revenue growth rate, operating leverage, and analyst upside.
Compare Workday and ServiceNow by HR vs IT workflow dominance, AI agent adoption, subscription growth, operating margins, and long-term valuation.
Compare Workday and Salesforce by HR and finance cloud leadership, AI monetisation, customer retention, free cash flow margins, and relative valuation.
Compare Veeva Systems and Salesforce by vertical vs horizontal SaaS moat, renewal rates, net revenue retention, operating margins, and analyst upside.
Compare Bill.com and Intuit by SMB financial workflow automation, payment volume, AI-driven accounting tools, revenue growth, margins, and valuation.
Compare Intuit and Adobe by AI product monetisation, subscription retention, TAM expansion potential, operating margins, free cash flow, and relative valuation.
Compare Twilio and Salesforce by communications API revenue, AI-driven engagement platform, enterprise customer growth, path to profitability, and valuation.
Compare Zoom and Microsoft by enterprise video and collaboration market share, AI meeting features, phone platform adoption, margin profile, and valuation.
Compare Atlassian and ServiceNow by developer platform adoption, AI automation traction, seat-based vs platform pricing, operating leverage, and analyst upside.
Compare Monday.com and Atlassian by product-led growth motion, enterprise expansion, AI workflow features, net revenue retention, and forward valuation.
Compare GitLab and Datadog by DevOps platform breadth, security tool integration, net retention, AI-assisted developer tools, gross margin, and analyst upside.
Compare Asana and Monday.com by revenue growth, net revenue retention, enterprise traction, AI workflow automation, path to profitability, and relative valuation.
Compare Five9 and Twilio by AI-powered contact center revenue, enterprise vs developer-first approach, gross margin, revenue growth, and analyst upside.
Compare SentinelOne and CrowdStrike by AI-native detection, ARR growth, platform consolidation wins, gross margin, path to profitability, and valuation.
Compare SentinelOne and Palo Alto Networks by AI-driven threat detection, platform breadth, enterprise deal size, billings growth, and analyst upside.
Compare CyberArk and CrowdStrike by privileged access management vs endpoint detection, platform expansion strategy, ARR growth, margins, and valuation.
Compare Okta and CrowdStrike by identity platform recovery, workforce identity revenue, endpoint security dominance, ARR growth, and analyst upside.
Compare Fortinet and Palo Alto Networks by network security appliance revenue, secure access service edge adoption, AI-driven threat prevention, margins, and valuation.
Compare Fortinet and CrowdStrike by on-premise vs cloud-native security approach, revenue growth, free cash flow margins, platform breadth, and long-term value.
Compare Tenable and Qualys by exposure management platform breadth, cloud security integration, recurring revenue growth, margins, and analyst upside.
Compare Okta and CyberArk by identity security platform scope, workforce vs machine identity revenue, customer expansion, operating leverage, and valuation.
Compare Moderna and BioNTech by post-COVID pipeline diversification, oncology programs, influenza vaccine traction, cash runway, and valuation.
Compare Gilead and AbbVie by oncology pipeline depth, HIV franchise durability, dividend yield, Humira transition risk, and long-term valuation.
Compare Vertex and Regeneron by rare disease franchise strength, pipeline beyond CF and Dupixent, revenue visibility, margins, and analyst upside.
Compare Merck and Bristol-Myers Squibb by Keytruda vs cancer portfolio breadth, patent cliff timing, pipeline depth, dividend yield, and relative valuation.
Compare Merck and AbbVie by Keytruda vs Skyrizi/Rinvoq revenue, pipeline diversification, dividend sustainability, and long-term earnings growth.
Compare Eli Lilly and Merck by obesity drug revenue ramp, Keytruda patent timeline, pipeline breadth, valuation premium vs discount, and analyst upside.
Compare Alnylam Pharmaceuticals and Vertex by RNA interference platform durability, CF franchise vs ATTR pipeline, revenue growth, and analyst upside.
Compare BioMarin Pharmaceutical and Alnylam by rare disease pipeline breadth, gene therapy vs RNAi platform, revenue growth, and long-term valuation.
Compare ConocoPhillips and Occidental by Permian production growth, balance sheet strength, oil price breakeven, dividend and buyback policy, and analyst upside.
Compare ConocoPhillips and ExxonMobil by LNG exposure, capital return yield, Guyana vs Permian growth, downstream earnings buffer, and long-term value.
Compare Diamondback Energy and Occidental by Permian Basin well productivity, operating costs, leverage, capital return framework, and analyst upside.
Compare Devon Energy and Occidental by variable dividend payout, Permian vs STACK basin exposure, free cash flow breakeven, debt reduction, and valuation.
Compare Enphase Energy and First Solar by microinverter vs panel manufacturing model, IRA domestic content benefits, gross margin profile, and analyst upside.
Compare First Solar and Bloom Energy by renewable energy technology approach, utility-scale vs commercial deployment, revenue visibility, margins, and upside.
Compare NextEra Energy and Southern Company by renewable energy growth, regulated utility earnings, dividend yield, rate base expansion, and analyst upside.
Compare NextEra Energy and American Electric Power by renewable capacity, rate base growth, dividend yield, capital spending, and valuation.
Sign in to access the full platform — compare any stocks, build watchlists, and get AI-powered portfolio insights.
Start Free Trial